| Literature DB >> 26372217 |
Lilian Motta Cantanhêde1, Cipriano Ferreira da Silva Júnior2, Marcos Massayuki Ito2, Kátia Paula Felipin1, Roberto Nicolete1, Juan Miguel Villalobos Salcedo1, Renato Porrozzi3, Elisa Cupolillo3, Ricardo de Godoi Mattos Ferreira1.
Abstract
Tegumentary Leishmaniasis (TL) is endemic in Latin America, and Brazil contributes approximately 20 thousand cases per year. The pathogenesis of TL, however, is still not fully understood. Clinical manifestations vary from cutaneous leishmaniasis (CL) to more severe outcomes, such as disseminated leishmaniasis (DL), mucosal leishmaniasis (ML) and diffuse cutaneous leishmaniasis (DCL). Many factors have been associated with the severity of the disease and the development of lesions. Recent studies have reported that the presence of Leishmania RNA virus 1 infecting Leishmania (Leishmania RNA virus 1, LRV1) is an important factor associated with the severity of ML in experimental animal models. In the present study, 156 patients who attended Rondonia's Hospital of Tropical Medicine with both leishmaniasis clinical diagnoses (109 CL; 38 ML; 5 CL+ML; 3 DL and 1 DCL) and molecular diagnoses were investigated. The clinical diagnosis were confirmed by PCR by targeting hsp70 and kDNA DNA sequences and the species causing the infection were determined by HSP70 PCR-RFPL. The presence of LVR1 was tested by RT-PCR. Five Leishmania species were detected: 121 (77.6%) samples were positive for Leishmania (Viannia) braziliensis, 18 (11.5%) were positive for Leishmania (V.) guyanensis, 3 (1.8%) for Leishmania (V.) lainsoni, 2 (1.3%) for Leishmania (Leishmania) amazonensis and 2 (1.3%) for Leishmania (V.) shawi. Six (3.9%) samples were positive for Leishmania sp. but the species could not be determined, and 4 (2.6%) samples were suggestive of mixed infection by L. (V.) braziliensis and L. (V.) guyanensis. The virus was detected in L. braziliensis (N = 54), L. guyanensis (N = 5), L. amazonensis (N = 2), L. lainsoni (N = 1) and inconclusive samples (N = 6). Patients presenting with CL+ML, DL and DCL were excluded from further analysis. Association between the presence of the virus and the disease outcome were tested among the remaining 147 patients (CL = 109 and ML = 38). Of them, 71.1% (n = 27) mucosal lesions were positive for LRV1, and 28.9% (n = 11) were negative. In cutaneous lesions, 36.7% (n = 40) were positive and 63.3% (n = 69) were negative for LRV1. The ratio P(ML|LRV1+)/P(ML|LRV1-) was 2.93 (CI95% 1.57...5.46; p<0.001), thus corroborating the hypothesis of the association between LRV1 and the occurrence of mucosal leishmaniasis, as previously described in animal models; it also indicates that LRV1 is not the only factor contributing to the disease outcome.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26372217 PMCID: PMC4570810 DOI: 10.1371/journal.pntd.0004079
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Fragments observed in agarose gels stained with GelRed.
Agarose gels [2% for (a) and (b), and 3.5% for (c) and (d)] stained with GelRed. a) PCR product of a fragment of the hsp70 gene of Leishmania. 50 bp: molecular weight marker of 50 base pairs; Lines 1–5: clinical samples positive for Leishmania; NC: negative control; PC: positive control and W: White. b) RT-PCR amplification of the ORF 1 fragment of LRV1. Lanes 1–4: clinical samples positive for LRV1; NC: negative control; PC: positive control and W: white. PCR-RFLP of hsp70 fragment digested with (c) HaeIII and (d) BstUI. 1: L. (V.) guyanensis; 2: L. (V.) shawi; 3: L. (V.) braziliensis; 4: L. (V.) lainsoni; 5: L. (L.) amazonensis; 6: Inconclusive sample and 7: White.
Fig 2Comparative frequency of LRV1 infection between the two most frequent clinical manifestations of ATL.
Frequency of the LRV1 infection is two times greater among ML than CL (p< 0.0001).
Observed frequencies of Leishmania sp. grouped by disease outcome and presence of LRV1.
| Outcome | Species | LRV1 | Total | |
|---|---|---|---|---|
| Positive | Negative | |||
| CL |
| 33 | 53 | 86 |
|
| 2 | 10 | 12 | |
|
| 1 | 2 | 3 | |
|
| 0 | 2 | 2 | |
| Inconclusive | 3 | 3 | 6 | |
| ML |
| 21 | 7 | 28 |
|
| 3 | 3 | 6 | |
| Inconclusive | 3 | 1 | 4 | |
| CL + ML |
| 2 | 3 | 5 |
| DL |
| 1 | 0 | 1 |
|
| 1 | 1 | 2 | |
| DCL |
| 1 | 0 | 1 |
| Total | 71 | 85 | 156 | |
CL: Cutaneous Leishmaniasis; ML: Mucosal Leishmaniasis; CL + ML: Cutaneous and Mucosal Leishmaniasis; DL: Disseminated Leishmaniasis and DCL: Diffuse Cutaneous Leishmaniasis.